AZN is currently covered by 13 analysts with an average potential upside of $43.93 (71.11%) from yesterday's end of day stock price of $63.25. AstraZeneca PLC activity chart has currently 55 price targets and 105 ratings on display.
Analysts average stock forecasts to be materialized ratio is 36.12% with an average time for these price targets to be met of 205.61 days.
Highest price target for AZN is $75, Lowest price target is $53, average price target is $64.
AstraZeneca is a biopharmaceutical company that has been at the forefront of discovering, developing, manufacturing, and commercializing prescription medicines since its incorporation in 1992. The company has gained worldwide recognition for its life-saving medicines that millions of people across the globe use. Its headquarters are in Cambridge, UK. The company has a portfolio of products that includes medicines for oncology, cardiovascular diseases, renal diseases, metabolism, respiratory and immunology, and rare diseases.
AstraZeneca’s commitment to discovering, developing, manufacturing, and commercializing life-saving medicines has made it famous in the biopharmaceutical industry. The company has a robust research and development program that includes partnerships with other companies and research institutions. AstraZeneca’s mission is to improve the health and well-being of people across the world by providing innovative medicines that address unmet medical needs.
AstraZeneca’s oncology portfolio includes a range of drugs used in the treatment of various types of cancer, including breast cancer, lung cancer, and ovarian cancer. Some of the most well-known products in this category are Tagrisso (osimertinib), Lynparza (olaparib), and Imfinzi (durvalumab)
AstraZeneca’s portfolio of drugs for cardiovascular, renal, and metabolism diseases includes treatments for high blood pressure, high cholesterol, and diabetes. Some of the most well-known products in this category are Brilinta/Brilique (ticagrelor), Brilinta/Brilique (ticagrelor), and Farxiga/Forxiga (dapagliflozin).
AstraZeneca’s respiratory and immunology portfolio includes treatments for asthma, chronic obstructive pulmonary disease (COPD), and other respiratory diseases. Some of the most well-known products in this category are Symbicort (budesonide/formoterol), Pulmicort (budesonide), and Fasenra (benralizumab).
AstraZeneca’s rare disease portfolio includes treatments for rare genetic disorders. Some of the most well-known products in this category are Soliris (eculizumab) and Ultomiris (ravulizumab)
AstraZeneca has developed and commercialized two COVID-19 vaccines: Vaxzevria and Evusheld. These vaccines have been authorized for emergency use in many countries around the world.
These are just some of the many products that AstraZeneca has developed and commercialized over the years. The company’s portfolio is constantly evolving as new drugs are discovered and approved for use by regulatory agencies around the world.
Currently, out of the existing stock ratings of AZN - 29 which are a Buy (78.38%), 8 which are a Hold (21.62%)
Current price target
Previous price target
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
2 months 15 days ago
4 months 3 days ago
4 months 9 days ago
4 months 28 days ago
5 months 7 days ago
What is AZN (AstraZeneca PLC) average time for price targets to be met?
Which analyst has the current highest performing score on AZN (AstraZeneca PLC) with a proven track record?
Which analyst has the most public recommendations on AZN (AstraZeneca PLC)?
Which analyst is the currently most bullish on AZN (AstraZeneca PLC)?
Which analyst is the currently most reserved on AZN (AstraZeneca PLC)?